# \[e-med\] La FIP et l'acc�s aux m�dicaments dans les PED **URL:** \ **Category:** e-med\ **Created:** [September 4, 2002, 4:47pm UTC](https://talk.edrugplus.org/t/e-med-la-fip-et-lacc-s-aux-m-dicaments-dans-les-ped/14881 "2002-09-04T16:47:12Z")\ **Posts on this page:** 1\ **Page:** 1
**Author:** ![remed9](https://avatars.discourse-cdn.com/v4/letter/r/22d042/32.png) [@remed9](https://talk.edrugplus.org/u/remed9)\ **Post date:** [September 4, 2002, 4:47pm UTC](https://talk.edrugplus.org/t/e-med-la-fip-et-lacc-s-aux-m-dicaments-dans-les-ped/14881/1 "2002-09-04T16:47:12Z")
E-MED: La FIP et l'acc�s aux m�dicaments dans les PED ------------------------------------------------------------------------- [Mod�rateur: Lisa Hayes de Health Action International a envoy� de communiqu� de presse de la F�d�ration International Pharmaceutique, il y aura peut-�tre des vagues dans la presse, car les interventions sont pr�c�d�es d'une conf�rence de presse. Remerciements � Ip-Health. CB] [http://www.cptech.org/ip/health/fip08312002.html](http://www.cptech.org/ip/health/fip08312002.html) FIP - International Pharmaceutical Federation World Congress of Pharmacy and Pharmaceutical Sciences 31 August � 5 September 2002, Nice, France MEDIA ANNOUNCEMENT International Pharmacists Explore Potential Roles for Improving Access to Medicines in Developing Countries during Pharmacy Information Symposium at FIP Congress in Nice One-third of the world�s population lacks access to essential medicines. In the poorest parts of Africa and Asia, this figure rises to one-half. 95% of TB cases and 98% of TB deaths occur in poor countries. Worldwide, 79% of people with TB do not have ready access to treatment. There are 300-500 million new cases of malaria each year, of which 1-2 million result in death. 95% of the 36 million people with HIV / AIDS live in developing countries. Research and development into diseases that affect the poor has stagnated because of the lack of economic incentives. The last major new TB drug was developed 30 years ago. Resistance to all infectious disease treatments is on the rise. The health statistics are frightening and the causes are no less upsetting. Many developing countries have pharmacy regulatory systems staffed with well-trained individualsthat are unable to operate due to lack of resources, corruption or ineffective laws. Some countries are unable to stop the flow of counterfeit drugs despite possessing the appropriate technical knowledge and equipment to do so and others do not have the resources to test new drugs that come on the market to ensure their quality. In many instances, countries do not have the drug management infrastructure and resources to effectively and efficiently procure, process, and distribute medicines. Where systems do exist to ensure delivery of medicines, the lack of resources often limits the extent to which patients can afford treatment. The Pharmacy Information Section of the International PharmaceuticalFederation (FIP) will host �Access and Equity: The challenge of getting medicines to the people who need them.� during FIP�s 62nd World Congress of Pharmacy and Pharmaceutical Sciences in Nice,France. The session, organised in collaboration with the World Health Organization�s Essential Drugs and Medicines Policy programme, will focus on the technical aspects of access to medicines, for which a pharmacist�s specialty skills are needed. A definition of the problem of access and its extent will be discussed, along with measures needed to address inadequate availability of medicines in developing countries. Price and quality are major issues, as is the need to prescribe, distribute, and use medicines appropriately. The profession�s and FIP�s potential roles will be discussed and the session will finish with a discussion among representatives from developing countries about how the pharmacy profession can contribute to increased access tomedicine for the world�s poor. As the world�s only international organisation representing the interests of pharmacy and pharmaceutical sciences, FIP�s role in supporting pharmacy organisations in developing countries is evolving. Through its close work with WHO and other health professions, FIP is working to increase North-South collaboration and transfer of knowledge and skills. By supporting and strengthening regional work in the global South, FIP is encouraging the creation of South-South co-operation, which will eventually lead to sustainable development in the area of access to medicines. Journalists are invited to attend the Press Briefing, which will take place on Wednesday, 4 September 2002, at 10.00am in Room Gallieni 2 at the Nice Acropolis. Below are details of Thursday�s symposium: Session Date/Time: Thursday, 5 September 2002, 9:00 � 12:00 Location: Acropolis, Room Hermes (Level 2) PRESENTATIONS Defining the issues: What constitutes access/equity, what impacts our ability to achieve it, and how extensive is the problem? David Lee, Management Sciences for Health (MSH), Panama and USA The contribution of the essential drugs concept to improved access Hans Hogerzeil, World Health Organization (WHO/EDM), Switzerland Neglected diseases and the impact of prices, pricing and patents Raffaella Ravinetto, M�decins Sans Fronti�res (MSF), Switzerland Ensuring drug products that are of acceptable quality Lembit R�go, World Health Organization (WHO/EDM), Switzerland Drug donations: Can they contribute to improved access? Serge Barbereau, R�seau M�dicaments et D�veloppement (ReMeD), France The profession's response: What can pharmacy and FIP do to help resolve the problem? John Bell, Commonwealth Pharmaceutical Association (CPA), Australia Panel discussion: Response from the field Developing country representatives For more information contact: Satu Siiskonen, FIP Project Coordinator Tel: +33 49 39 28 422 in Nice, France until 5 September Tel.: +31 70 302 1970 in The Hague Fax: +31 70 302 1999 E-mail: fip@fip.org Website [http://www.fip.org](http://www.fip.org) -- Adresse pour les messages destin�s au forum E-MED: \ Pour r�pondre � un message envoyer la r�ponse au forum ou directement � l'auteur. Pour toutes autres questions addresser vos messages � : \